eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize natureâ€™s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-24	US$6.950	-2.80%	1,532
26-08-21	US$7.150	+1.56%	10,232
26-08-20	US$7.040	+10.00%	13,691
26-08-19	US$6.400	+0.16%	3,122
26-08-18	US$6.390	+5.97%	3,049

Delayed Quote Nasdaq

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq 16:30:00 2026-08-24 EDT			5-day change	1st Jan Change
6.950 ^USD	-2.80%		+15.26%	-36.24%

08-13	EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-24	EXoZymes receives $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery	CI

Market Cap	64.51M 55.28M 51.72M 47.28M 89.22M 6.18B 90.17M 612M 238M 3.1B 242M 237M 10.26B	P/E 2024	-18.5x	P/E 2025	-9.97x
Enterprise Value	62.71M 53.74M 50.28M 45.96M 86.74M 6B 87.66M 595M 231M 3.02B 235M 230M 9.98B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	35.47%	Yield 2024 *	-	Yield 2025	-

08-13	EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-24	EXoZymes receives $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery	CI
06-08	EXoZymes Prices $5.3 Million Offering	MT
05-14	EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Exozymes Inc - announces common stock offering - SEC filing	RE
03-30	EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-05	EXoZymes Inc. Reports Detailed Downline Performance Results from Its Recently Completed 100-liter Pilot Production Run of NCT	CI
12-12	EXoZymes, Inc. Achieves 100 Scale-Up of N-Trans-Caffeoyltyramine Production Process Using Its Proprietary Exozyme-Based, Cell-Free Biomanufacturing Platform	CI
11-13	EXoZymes, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-10	Certain Options of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI
11-10	Certain Restricted Stock Units of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI
11-10	Certain Common Stock of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI

08-20	EXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today	AQ
08-18	EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets	AQ
08-11	EXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026	AQ
07-23	EXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing	AQ
06-24	EXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery	AQ

eXoZymes, Inc. Stock

Stocks

EXOZ

US4618741098

Biotechnology & Medical Research

Valuation: eXoZymes, Inc.

Chart: eXoZymes, Inc.

Latest news : eXoZymes, Inc.

Press Releases: eXoZymes, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: eXoZymes, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-2.80%
1 week	+15.26%
Current month	+49.46%
1 month	+47.56%
3 months	-29.94%
6 months	-22.78%
Current year	-36.24%

1 week	6.08	8.01
1 month	4.35	8.01
Current year	4.35	13.4
1 year	4.35	18.4
3 years	4.35	23.99
5 years	4.35	23.99
10 years	4.35	23.99

Manager	Title	Age	Since
Michael Heltzen CEO	Chief Executive Officer	45	2024-01-31
Paul Opgenorth CTO	Chief Tech/Sci/R&D Officer	43	2019-03-31
Tyler Korman CTO	Chief Tech/Sci/R&D Officer	47	2019-03-31

Director	Title	Age	Since
James Bowie BRD	Director/Board Member	66	2019-03-31
Chris Marlett CHM	Chairman	61	2025-02-20
Anthony DiGiandomenico BRD	Director/Board Member	59	2019-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/9/26	Tyler Korman	Sell	Founder	1,500	0.0179%
7/2/25	Michael Heltzen	Buy	Chief Executive Officer	1,040	0.0128%
6/17/25	Michael Heltzen	Free	Chief Executive Officer	235,817	2.9015%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXOZYMES, INC.	-2.80%	+15.26%	-25.35%	-	66.36M
LONZA GROUP AG	-0.74%	+3.78%	+3.74%	+23.10%	51.61B
REVOLUTION MEDICINES, INC.	+1.01%	-0.20%	+471.68%	+564.93%	44.89B
IQVIA HOLDINGS INC.	+0.16%	+7.88%	+36.14%	+20.76%	42.77B
BEONE MEDICINES AG	-0.66%	+2.61%	+18.59%	+87.04%	42.58B
CELLTRION, INC.	+0.88%	-3.48%	+17.20%	+53.83%	31.82B
MEDPACE HOLDINGS, INC.	-0.12%	+3.84%	+33.73%	+145.25%	17.33B
ASCENDIS PHARMA A/S	-0.53%	+1.84%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.58%	+4.66%	+7.17%	+30.87%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.15%	+4.17%	+84.49%	+50.33%	14.09B
Average	-0.11%	+6.05%	+71.93%	+122.01%	27.65B
Weighted average by Cap.	+0.10%	+4.11%	+100.55%	+140.63%

	2024	2025
Net sales	-	-
Net income	-5.86M -5.02M -4.7M -4.3M -8.11M -561M -8.19M -55.61M -21.62M -282M -22.01M -21.53M -932M	-9.16M -7.85M -7.34M -6.71M -12.67M -877M -12.8M -86.89M -33.79M -440M -34.39M -33.64M -1.46B
Net Debt	-8.33M -7.14M -6.68M -6.11M -11.53M -798M -11.65M -79.05M -30.74M -401M -31.29M -30.61M -1.33B	-1.8M -1.54M -1.44M -1.32M -2.48M -172M -2.51M -17.04M -6.63M -86.36M -6.74M -6.6M -286M